Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc
 
 
Facebook
 
ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Mirtazapine For Fibromyalgia: An Effective Treatment Option?

Thursday 7 June 2018

 

From MPR:

 

Fibromyalgia
Mirtazapine appears to be an
effective option for fibromyalgia.
 

Mirtazapine for Fibromyalgia: An Effective Treatment Option?

By
June 5, 2018
Copyright © 2018 Haymarket Media, Inc. All Rights Reserved.

The antidepressant mirtazapine appears to be a safe and effective treatment option for patients with fibromyalgia, according to a systematic review published in Rheumatology International.

Mirtazapine is a central alpha-2 antagonist currently FDA-approved for the treatment of major depressive disorder. It is a potent antagonist of 5-HT2 and 5-HT3 serotonin receptors, as well as H1 histamine receptors. "A key difference when compared to other treatment options is that mirtazapine targets many of the symptoms of fibromyalgia with its mechanism of action and simple once daily dosing," explained the authors.

To investigate the role of mirtazapine for fibromyalgia, researchers searched various database and identified 3 randomized, placebo-controlled studies and 1 open-label trial that fit the inclusion criteria. The selected studies lasted 6 to 13 weeks in duration, included mirtazapine doses ranging from 15 to 30mg daily, and evaluated improvements in pain, sleep, and quality of life.

 

Full article…

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page